Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Messenger RNA (mRNA) vaccines offer flexible cancer immunotherapy by encoding tumor-specific antigens.
• Melanoma is a key model for mRNA vaccine development due to its mutational burden and response to immunotherapy.
• Innovations in mRNA delivery systems address challenges in stability, targeting, and immunogenicity.

Purpose of the Study:

• To evaluate the efficacy of a personalized neoantigen mRNA vaccine (mRNA-4157/V940) in combination with pembrolizumab for resected high-risk melanoma.
• To assess the impact of this combination therapy on recurrence-free survival (RFS) and distant metastasis-free survival (DMFS).

Main Methods:

• A randomized phase IIb clinical trial (KEYNOTE-942) was conducted.
• Patients received either mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone.
• Recurrence-free survival and distant metastasis-free survival were the primary endpoints.

Main Results:

• The combination of mRNA-4157 (V940) and pembrolizumab significantly prolonged recurrence-free survival compared to pembrolizumab alone (HR 0.561).
• At 18 months, RFS was 79% for the combination arm versus 62% for pembrolizumab alone.
• A 3-year update showed sustained RFS benefit (74.8% vs. 55.6%) and improved DMFS in resected high-risk melanoma patients.

Conclusions:

• Personalized neoantigen mRNA vaccines represent a promising advancement in cancer immunotherapy for melanoma.
• The combination of mRNA-4157 (V940) with pembrolizumab demonstrates significant and sustained clinical benefit.
• Future applications may see mRNA vaccines becoming a mainstay therapy for melanoma and other cancers.